Most had no idea what they actually consumed.
Em Campinas, um jovem que acreditava estar consumindo ecstasy chegou às portas da morte por uma substância que nunca havia sido testada em seres humanos — um opioide sintético cinquenta vezes mais potente que o fentanil, misturado ao que ele pensava conhecer. O caso, identificado por pesquisadores da Unicamp, não é apenas uma história de intoxicação individual: é um espelho de uma crise coletiva, em que a ignorância sobre o que se consome se torna, ela mesma, o maior fator de risco. Enquanto o Brasil age para proibir a substância, especialistas alertam que a proibição, sem infraestrutura de testagem e políticas de redução de danos, chega sempre depois do perigo.
- Um paciente perdeu a consciência e entrou em colapso respiratório após consumir ecstasy adulterado com um opioide nunca antes detectado no Brasil — e só sobreviveu porque a equipe médica reconheceu os sinais e administrou naloxona a tempo.
- O N-pirrolidino protonitazeno, cinquenta vezes mais potente que o fentanil, nunca foi aprovado como medicamento nem testado em humanos — foi abandonado décadas atrás justamente por não ter dose segura conhecida.
- Um estudo com 1.631 frequentadores de festas revelou que quase 71% usam substâncias ilícitas, mas a maioria desconhece o que realmente consome — os laboratórios encontraram um mosaico crescente de compostos sintéticos emergentes nas amostras.
- Os testes colorimétricos usados por grupos de redução de danos foram desenvolvidos para drogas clássicas e falham diante das novas substâncias sintéticas, deixando um vácuo perigoso entre o que circula nas festas e o que pode ser identificado.
- A Anvisa baniu a substância em julho, mas especialistas alertam que a resposta regulatória reativa não é suficiente — sem políticas estruturais de testagem e redução de danos, o próximo caso pode não ter o mesmo desfecho.
Um paciente deu entrada no hospital universitário de Campinas em 19 de junho com o que parecia ser uma intoxicação por ecstasy. Mas os sintomas não batiam: sonolência profunda, perda de consciência, respiração comprometida. A equipe administrou naloxona — o antídoto para opioides — e ele sobreviveu. Quando o centro de toxicologia da Unicamp analisou seu sangue, encontrou algo inédito no país: N-pirrolidino protonitazeno, um opioide sintético aproximadamente cinquenta vezes mais potente que o fentanil, misturado à droga que ele havia consumido numa festa.
A substância pertence à família dos nitazenos — compostos sintetizados décadas atrás como potenciais analgésicos, mas abandonados pela medicina justamente porque não apresentavam margem terapêutica segura. Em doses elevadas, suprimem o sistema nervoso central até paralisar o centro respiratório. Nunca foram aprovados, nunca foram testados em humanos. Este chegou ao Brasil sem nenhum desses filtros.
O caso isolado abriu uma janela para um problema muito maior. Uma pesquisa conduzida entre 2022 e meados de 2025, com amostras de saliva coletadas em festas por todo o Brasil, mostrou que quase 71% dos participantes usavam substâncias ilícitas — e que a maioria não sabia o que realmente havia consumido. Além de MDMA, cocaína e metanfetamina, os laboratórios identificaram uma constelação crescente de compostos emergentes: MDEA, desclorocetamina, dipentilona, catinonas sintéticas. Substâncias que se combinam de formas imprevisíveis entre si e com medicamentos de uso comum.
José Luiz da Costa, coordenador do centro de toxicologia, aponta para uma falha sistêmica: os testes colorimétricos disponíveis para grupos de redução de danos foram desenvolvidos para drogas clássicas e não conseguem identificar os novos sintéticos. A Anvisa baniu o N-pirrolidino protonitazeno em julho, mas a proibição reativa não resolve o problema estrutural. Sem infraestrutura de testagem adequada e sem políticas orientadas à redução de danos, o Brasil permanece vulnerável a substâncias que chegam antes de qualquer resposta institucional. O paciente de Campinas sobreviveu. A pergunta que fica é por quanto tempo essa sorte se repetirá.
A patient arrived at the teaching hospital in Campinas with a story that would soon alarm public health officials across Brazil. He had taken what he believed was ecstasy at a party, but within hours he was drowsy, then unconscious, his breathing shallow and labored. The emergency team administered naloxone—the opioid antidote—to pull him back from the edge of respiratory failure. When researchers at Unicamp's toxicology center analyzed his blood, they found something that had never been detected in Brazil before: N-pirrolidino protonitazeno, a synthetic opioid roughly fifty times more potent than fentanyl, mixed into the ecstasy he had consumed.
The patient arrived at the hospital on June 19th. By early July, the toxicology center had notified Brazil's rapid-alert system for drugs. By late July, the national health agency had moved to ban the substance outright. But the real concern was not just this one case—it was what the case revealed about how little people actually know about what they're putting into their bodies.
José Luiz da Costa, who coordinates the toxicology center, explained the mechanics of the danger. When someone ingests a nitazeno, the first sensation is profound relaxation. At higher concentrations, the drug suppresses the central nervous system so severely that the respiratory center simply stops working. Death follows. What made this particular compound especially alarming was that it had never been tested on humans, never approved as a medication, never studied for safety margins. Some nitazenos were synthesized decades ago as potential painkillers, but they were abandoned precisely because they offered no therapeutic window—no safe dose. This one had skipped even that history.
The real picture emerged from a study conducted between 2022 and mid-2025, when researchers collected saliva samples from 1,631 people at parties across Brazil. Nearly 71 percent reported using illicit drugs. But here was the critical finding: most of them had no idea what they actually consumed. The lab results showed MDMA, cocaine, and methamphetamine as the dominant substances, but also a growing constellation of newer compounds—MDEA in 9.3 percent of samples, desclorocetamina in 3.1 percent, dipentilona in 2.9 percent, and synthetic cathinones in 2.4 percent. The drugs were mixing, layering, creating unpredictable interactions in the brain.
Da Costa pointed to a systemic failure. When someone takes a contaminated drug alongside, say, an antidepressant, the effects amplify in ways no one can predict. The same receptors in the brain receive all these signals at once. The person has no way to know what they're actually ingesting. This is not a matter of individual choice or risk tolerance—it is a public health crisis born from ignorance.
Brazil, he argued, lacks the infrastructure to address it. Some harm-reduction groups have begun offering colorimetric testing—simple chemical tests that change color in the presence of certain drugs. But these tests work poorly for the new substances flooding the market. They were designed for classical drugs. They cannot distinguish between the emerging synthetics. Without better testing, without policies designed to reduce harm rather than simply punish use, Brazil faces a scenario where people will continue to consume substances they cannot identify, mixed with compounds they do not expect, in doses they cannot control. The patient in Campinas survived. The next one might not.
Citas Notables
These substances mixed together cause unexpected effects. People use mixed drugs and may also be taking antidepressants. This ends up amplifying the effects, with the same brain receptors receiving all these stimuli at once.— José Luiz da Costa, coordinator of Unicamp's toxicology center
Some nitazenos were synthesized in the past as attempts to be painkilling drugs, but never reached the market because they had no therapeutic safety margin. This particular compound was never even tested.— José Luiz da Costa
La Conversación del Hearth Otra perspectiva de la historia
Why did this particular case matter enough to trigger a national alert?
Because it was the first time this specific compound had been found in Brazil, and it was found in someone who nearly died. The patient's blood told a story about what's actually circulating in the drug supply—not what we think is circulating.
The patient thought he was taking ecstasy. How does something this dangerous end up mixed into ecstasy?
That's the question no one can answer with certainty. It could be intentional adulteration, or it could be cross-contamination in an illegal lab. Either way, the person consuming it has zero way to know. They're making a choice about one drug and getting fifty times more potent opioid instead.
The study found that 71 percent of party-goers use illicit drugs but don't know what they're taking. Isn't that the real story?
It is. The individual case is dramatic, but the pattern is the crisis. Thousands of people are consuming substances they cannot name, in combinations they cannot predict. The system has no way to warn them or test what they're about to use.
Why can't the colorimetric tests identify these new drugs?
They were designed for older compounds. They work by color change, which is reliable for classical drugs but not sensitive enough for these new synthetics. You'd need more sophisticated testing—mass spectrometry, things that require lab equipment and trained technicians.
So what would harm reduction actually look like here?
Testing services at venues. Education about what's actually in the supply. Medical protocols for overdose. Decriminalization so people seek help without fear. Brazil has almost none of this infrastructure.
Is there any reason to think this compound will stay rare, or should we expect to see it again?
Once a drug appears once, it tends to appear again. The synthesis is known now. The question is whether Brazil will build the systems to detect it before it causes deaths.